Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | TNKS | O95271 | 12/20 | 0.66 |
| ▸ | PARP1 | P09874 | 6/20 | 0.66 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | MAOB | P27338 | 2/20 | 0.66 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 6/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | GABRP | O00591 | 2/20 | 0.64 |
| ▸ | GABRD | O14764 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28152153 | 0.88 | TNKS (0.69) | FTOLCKTNKSPARP1TNKS2 | |
| SCHEMBL30000045 | 0.84 | FTO (1.00) | FTOLCKTNKSPARP1TNKS2 | |
| SCHEMBL1883775 | 0.84 | FTO (1.00) | FTOLCKTNKSPARP1TNKS2 | |
| SCHEMBL14491047 | 0.84 | PTPRS (0.74) | FTOLCKTNKSPARP1TNKS2 | |
| SCHEMBL1483977 | 0.83 | TNKS (0.77) | FTOLCKTNKSPARP1TNKS2 | |
| SCHEMBL312104 | 0.82 | TNKS (0.66) | FTOLCKTNKSPARP1TNKS2 | |
| SCHEMBL311820 | 0.82 | FTO (0.78) | FTOLCKTNKSPARP1TNKS2 | |
| Flavone SCHEMBL27686205 | 0.81 | TNKS (0.84) | TNKSPARP1TNKS2SMN1; SMN2KDM4E | |
| SCHEMBL24046756 | 0.81 | GABRP (0.64) | TNKSSMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL8782363 | 0.81 | FTO (0.68) | FTOLCKTNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | claimed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | claimed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | claimed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | claimed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | claimed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | claimed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | FTO 4018/4885LCK 4224/4885TNKS 4486/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | FTO 4018/4885LCK 4224/4885TNKS 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.